Sales Dependence on Specific Pharmaceutical Companies
First written in FY2016. 1 of 8 entries say "Worsened", first in FY2017. Latest entry: FY2026.
1 other company's latest entry also says "Other".
- FY2026Changes in customer composition and a lower share of the largest customerAnnual report
「PFIZER, INC. 1,259,365 14.5 Philip Morris International Inc. 1,180,271 13.6」
PFIZER's share of sales to major customers fell from 20.6% in the previous fiscal year to 14.5%, while Philip Morris International Inc. newly accounted for 13.6%. Concentration in certain customers remains, but the customer mix is changing. - FY2024MitigatedAnnual report
「To date, the Company has primarily done business with major pharmaceutical companies holding numerous promising development programs in Japan. As the quality of its services has been recognised by customers, its sales concentration in certain domestic pharmaceutical companies became relatively high. However, this has improved as the Company expanded its overseas business and increased its customer base.」
The Company explains that its sales concentration in certain domestic pharmaceutical companies has improved as a result of overseas business expansion and an increase in the number of customers. In the current fiscal year, PFIZER accounted for 15.5% and Eisai for 11.5%. - FY2021Lower combined dependence on the 3 major customers and changes in customer compositionAnnual report
「CHUGAI PHARMACEUTICAL CO.,LTD. 1,521,281 14.8 エーザイ株式会社 1,488,231 14.5 小野薬品工業株式会社 727,047 7.1」
Revenue dependence on the 3 largest customers was 36.4%, down from 41.4% in the previous fiscal year. The customer mix comprised Chugai Pharmaceutical, Eisai and Ono Pharmaceutical, indicating continued dependence on certain major pharmaceutical companies. - FY2020Lower combined dependence on the 3 major customers and changes in customer compositionAnnual report
「Eisai Co.,Ltd. ¥1,548,437 thousand, 14.2%; ONO PHARMACEUTICAL CO.,LTD. ¥1,513,098 thousand, 13.8%; CHUGAI PHARMACEUTICAL CO.,LTD. ¥1,468,841 thousand, 13.4%」
Dependence on the 3 major customers totaled 41.4%, down from 43.8% in the previous fiscal year. Dependence on the 3 companies continued, while Eisai Co.,Ltd.'s share increased from 10.1% to 14.2%. - FY2019Lower combined dependence on the 3 major customers and changes in customer compositionAnnual report
「ONO PHARMACEUTICAL CO.,LTD. ¥2,187,693 thousand, 19.3%; CHUGAI PHARMACEUTICAL CO.,LTD. ¥1,631,041 thousand, 14.4%; Eisai Co.,Ltd. ¥1,146,659 thousand, 10.1%」
Dependence on the 3 major customers totaled 43.8%, down from 46.5% in the previous fiscal year. Meanwhile, the customer composition changed from Shionogi & Co.,Ltd. to Eisai Co.,Ltd., while dependence on specific major pharmaceutical companies continued. - FY2018Lower combined dependence on the 3 major customers and changes in customer compositionAnnual report
「ONO PHARMACEUTICAL CO.,LTD. ¥2,006,256 thousand, 22.0%; CHUGAI PHARMACEUTICAL CO.,LTD. ¥1,684,876 thousand, 18.5%; Shionogi & Co.,Ltd. ¥550,217 thousand, 6.0%」
Dependence on the 3 major customers totaled 46.5%, down from 48.7% in the previous fiscal year. However, CHUGAI PHARMACEUTICAL CO.,LTD.'s share increased from 13.0% to 18.5%, indicating continued dependence on specific customers. - FY2017WorsenedAnnual report
「ONO PHARMACEUTICAL CO.,LTD. ¥2,050,819 thousand, 24.5%; CHUGAI PHARMACEUTICAL CO.,LTD. ¥1,089,567 thousand, 13.0%; Shionogi & Co.,Ltd. ¥935,036 thousand, 11.2%」
Dependence on the 3 major customers totaled 48.7%, up from 44.4% in the previous fiscal year. In particular, ONO PHARMACEUTICAL CO.,LTD.'s share increased from 19.7% to 24.5%, quantifying the customer concentration risk more clearly. - FY2016First statedAnnual report
「The Group's policy is to conduct business primarily with major pharmaceutical companies that have many promising development products. As a result, its dependence on specific pharmaceutical companies is relatively high.」
The company discloses the proportion of sales attributable to major customers, including ONO PHARMACEUTICAL CO.,LTD., Shionogi & Co.,Ltd. and CHUGAI PHARMACEUTICAL CO.,LTD., and identifies customer concentration as a risk.